Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers?

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages 183-185

  Duda, Dan G ^a   Ancukiewicz, Marek ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CEDIRANIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEALTH CARE COST; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; BLOOD; DIET THERAPY; LUNG TUMOR; NOTE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74949105013     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.8021     Document Type: Editorial

References (24)

1. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
2. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
3. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
4. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
5. Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
6. Jain RK: A new target for tumor therapy. N Engl J Med 360:2669-2671, 2009
7. Kamoun WS, Ley CD, Farrar CT, et al: Edema control by cediranib, a VEGF targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552, 2009
8. Hamzah J, Jugold M, Kiessling F, et al: Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453:410-414, 2008
9. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008
10. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234, 2009
11. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
12. Dowlati A, Gray R, Johnson DH, et al: Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 24S:7027, 2006
13. Hanrahan EO, Lin HY, Kim ES, et al: Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28:193-201, 2010
14. Sorensen AG, Batchelor TT, Zhang WT, et al: A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-5300, 2009
15. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha- deficient colon cancer cells. Nat Med 11:992-997, 2005
16. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature, and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
17. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 27:3020-3026, 2009
18. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27:3027-3035, 2009
19. Shojaei F, Wu X, Malik AK, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25:911-920, 2007
20. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
21. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
22. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
23. Heymach JV, Paz-Ares L, De Braud F, et al: Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415, 2008
24. Hanrahan EO, Ryan AJ, Mann H, et al: Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small-cell lung cancer. Clin Cancer Res 15:3600-3609, 2009